Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|4/29/2020||RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
... been € 341.9 million, +9.4%. Dividend for 2019 € 1.00 per share (+8.7% vs 2018), of which € 0.48 already paid in November 2018. Number of Board members increased from eleven to twelve. New members appointed: Francesco Balestrieri, Giorgio De Palma, Guido Guidi and Piergiorgio Peluso (independent). Alfredo Altavilla appointed non executive Chairman ...
|4/11/2019||Shionogi Concludes a Contract for the Commercialization of Rizmoic® (naldemedine), an Opioid-Induced Constipation Therapeutic Agent, in Germany, the UK, and the Netherlands
OSAKA, Japan & AMSTERDAM- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced today that Shionogi concluded a distribution contract with Sandoz (Headquarters: Holzkirchen, Germany; CEO a.i: Francesco Balestrieri hereinafter “Sandoz”) for the sale of Rizmoic® (naldemedine) for the treatment of opioid-induced constipation (OIC ...
|4/11/2019||How far will Novartis’ Sandoz go to ‘differentiate’ itself? Into branded drugs, apparently
... markets of Germany, the U.K. and the Netherlands. The drug won its U.S. nod in mid-2017 and just bagged official European approval in late February. In a Thursday statement, interim Sandoz chief Francesco Balestrieri framed the deal as “a significant step forward” for Sandoz's goal of “focusing increasingly on ...
|4/11/2019||How far will Novartis’ Sandoz go to ‘differentiate’ itself? Into branded drugs, apparently||FiercePharma|